



Epichem Awarded Contract Extension from DNDi

21 December 2020 – Perth, Australia: PharmAust Limited (ASX:PAA), a clinical-stage oncology company, is pleased to announce that its wholly owned subsidiary, Epichem Pty Ltd, has been awarded an extension to its current contract with Drugs for Neglected Diseases *initiative* (DNDi) (www.dndi.org).

The contract renewal will see Epichem continue to provide its synthetic and medicinal chemistry expertise to support DNDi's drug discovery projects, aimed at developing new treatments for neglected diseases, until 31st December 2021. The extension is expected to generate up to AUD\$1.02M in revenues for Epichem during CY 2021.

Epichem's CEO, Mr Colin La Galia said "We are delighted that the contract with DNDi has been renewed for another year and excited by what we can achieve together in partnership to deliver the expected outcomes with our dedicated team of chemists. This will mark our 13th year with DNDi supporting their important work and we look forward to continuing our long-standing and important relationship with them."

PharmAust's Chairman Dr Roger Aston said "It is tremendous that Epichem have secured a further extension to this work with such a leading R&D organisation as DNDi".

This announcement is authorised by the Board.

Enquiries:

Mr Colin La Galia
CEO Epichem
Tel: 08 6167 520
colin.lagaliam@epichem.com.au

Dr Roger Aston
Executive Chairman
Tel: 0402 762 204
rogeraston@pharmaust.com

About Epichem:

Epichem is a wholly owned subsidiary of the ASX listed company PharmAust Limited. Located in Technology Park, Western Australia, Epichem has been delivering products and services in synthetic and medicinal chemistry to the global drug discovery and pharmaceutical industries in over 40 countries worldwide for over 17 years. Epichem has newly constructed purpose-built, state-of-the-art laboratories and has world class equipment and expertise in synthetic and medicinal chemistry to support drug discovery projects, and for the cost-effective synthesis of drug analogue libraries and intermediates. It also has a rapidly growing catalogue of pharmaceutical reference standards. Epichem is the winner of the WA Industry Export Award 2019 for International Health, the 2020 Inspiring Story of Celebrating Remarkable Resilience Nomination for WA for the Australian Export and Investment Awards and the 2020 GHP Biotechnology Award winner for Most Innovative Chemistry Service Provider – Australia and Best in Organic Chemistry Solutions 2020. Epichem generated Aus\$3.5M in revenues in the 2020 FY. For more information, visit www.epichem.com.au

About DNDi

DNDi is a not-for-profit product development partnership working to research and develop new treatments for neglected diseases, in particular human African trypanosomiasis, leishmaniasis, Chagas disease, malaria, paediatric HIV, and specific helminth-related infections. DNDi was established in 2003 by the Oswaldo Cruz Foundation from Brazil, the Indian Council for Medical Research, the Kenya Medical Research Institute, the Ministry of Health of Malaysia, Pasteur Institute, and Médecins sans Frontières (MSF). WHO/TDR acts as a permanent observer. Since 2007, DNDi has delivered four treatments: two fixed-dose anti-malarials (ASAQ and ASMQ), NECT (nifurtimox-eflornithine combination therapy for sleeping sickness), and SSG&PM, a combination therapy to treat visceral leishmaniasis in Africa. For more information visit, www.dndi.org